Rhode Island Senate Bill S2076

Rhode Island 2022 Regular Session

• Introduced: 1/25/22
• Refer: 1/25/22

Caption

Prescription Drug Cost Protection

Impact

If enacted, this legislation will have significant implications for state healthcare and insurance markets. It prohibits state entities and participating health plans from purchasing referenced drugs at prices exceeding the referenced rate. This could lead to substantial savings for the state and potentially lower out-of-pocket costs for consumers. Additionally, the bill mandates that any savings derived from compliance with this act must be applied directly to reduce costs for consumers, thus reinforcing the intent to make prescription medications more accessible.

Summary

S2076, also known as the Prescription Drug Cost Protection Act, aims to control costs associated with prescription drugs purchased by state entities and health plans. The bill sets forth provisions to ensure that these entities do not pay more than a specified rate for certain high-cost prescription drugs. The referenced rate will be established based on a comparison of wholesale acquisition costs and prices from various Canadian drug lists, ensuring that the state purchases medications at a fair and affordable price.

Contention

One notable point of contention surrounding S2076 is the penalties imposed on manufacturers and distributors who fail to comply with the negotiation and pricing provisions. The bill states that manufacturers that do not negotiate in good faith face a penalty of up to $500,000 or the amount of annual savings determined by the superintendent of insurance. Opponents may argue that such measures could deter pharmaceutical companies from supplying drugs to the state, ultimately restricting access for patients who depend on those medications. Furthermore, the requirement for transparency in pricing and the establishment of a ceiling price derived from overseas pricing might lead to debates about market dynamics and pharmaceutical innovation.